Evidence map›Paper›PMID 34291407›Full record

ReviewTherapeutic innovation & regulatory science2022

Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]).

Folker Spitzenberger, Jaimin Patel, Inga Gebuhr, Klaus Kruttwig, Abdulrahim Safi, Christian Meisel

Open access · hybridAbstract readReview
In one paragraph

Review in Therapeutic innovation & regulatory science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
15.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Folker SpitzenbergerCentre for Regulatory Affairs in Biomedical Sciences, Technische Hochschule Lübeck, Mönkhofer Weg 239, 23562, Lübeck, Germany. folker.spitzenberger@th-luebeck.de.ORCID http://orcid.org/0000-0001-9434-0599
Jaimin PatelCentre for Regulatory Affairs in Biomedical Sciences, Technische Hochschule Lübeck, Mönkhofer Weg 239, 23562, Lübeck, Germany.
Inga GebuhrLabor Berlin - Charité Vivantes GmbH, Sylter Strasse 2, 13353, Berlin, Germany.
Klaus KruttwigCentre for Regulatory Affairs in Biomedical Sciences, Technische Hochschule Lübeck, Mönkhofer Weg 239, 23562, Lübeck, Germany.
Abdulrahim SafiCentre for Regulatory Affairs in Biomedical Sciences, Technische Hochschule Lübeck, Mönkhofer Weg 239, 23562, Lübeck, Germany.
Christian MeiselLabor Berlin - Charité Vivantes GmbH, Sylter Strasse 2, 13353, Berlin, Germany.
Technical University of Applied Sciences Lübeck · DEVivantes Klinikum · DELeibniz Institute of Photonic Technology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed at the development of a regulatory strategy for compliance of laboratory-developed tests (LDTs) with requirements of the Regulation (EU) 2017/746 ("EU-IVDR") under consideration of international requirements for LDTs as established in major regulatory regions. Furthermore, it was analysed in how far elements of current LDT regulation could qualify for an internationally harmonised concept ensuring quality, safety and performance of LDTs.

methodsA review of regulatory literature including legislation as well as guidance documents was performed. The regulatory strategy was adapted from international guidance concepts used for commercially marketed IVD. It was then applied to the example of a large medical laboratory in the EU. A high-level comparison was conducted to identify gaps and matches between the different international regulatory requirements for LDTs.

resultsA four-step strategy for compliance of LDTs with the EU IVDR was implemented in an exemplary medical laboratory. On the basis of an internationally used LDT definition, LDTs constitute nearly 50% of the total IVD devices used in the laboratory. While an ISO 15189-compliant QMS is a major component, it should be accompanied by the application of appropriate processes for risk management, performance evaluation and continuous monitoring of LDTs. At least six criteria represent common characteristics of a potential, internationally convergent concept for the regulation/standardization of LDTs.

conclusionsThis study confirms the impact of LDTs for individualized and innovative medical laboratory testing. Prerequisites for LDT use as especially given by the IVDR and missing interpretation in the EU with regard to the scope of LDT definition, the application of standards and the extent of documentation for LDTs currently lead to uncertainties for both laboratories and regulatory bodies responsible for LDT oversight. The characteristics identified as common criteria for ensuring quality, safety and performance of LDTs may be considered as central elements of future international consensus guidance.

Indexed as

LaboratoriesReagent Kits, DiagnosticReference StandardsReagent Kits, DiagnosticConformity assessmentIn-house IVDIVDRLaboratory-developed testsLDTValidation

Identifiers

PMID34291407
PMCPMC8294224
OpenAlexW3185912133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.